GC Biopharma

GC Biopharma Enterprise Value

The Enterprise Value (EV) of GC Biopharma (006280.KS) as of Oct 26, 2026 is 2.24 T KRW. In the previous year, Enterprise Value (EV) was 2.33 T KRW — a change of -3.69% (lower).

Enterprise Value

2.24 TKRW

YoY

-3.69%

Last updated:

Enterprise Value (EV) of GC Biopharma is 2025 2.24 T KRW. Enterprise Value (EV) of GC Biopharma was 2024 2.33 T KRW. It decreases by -3.69% lower compared to the previous year.

The GC Biopharma Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
2.32 T KRW
Jan 1, 2019
2.40 T KRW
Jan 1, 2020
2.18 T KRW
Jan 1, 2021
2.27 T KRW
Jan 1, 2022
2.27 T KRW
Jan 1, 2023
2.07 T KRW
Jan 1, 2024
2.33 T KRW
Jan 1, 2025
2.24 T KRW
The GC Biopharma Enterprise Value history
YEAREnterprise ValueYoY
2.24 TKRW-3.69%
2.33 TKRW+12.28%
2.07 TKRW-8.55%
2.27 TKRW-0.07%
2.27 TKRW+3.95%
2.18 TKRW-8.86%
2.40 TKRW+3.35%
2.32 TKRW+0.69%
2.30 TKRW+2.87%
2.24 TKRW+1.92%
2.20 TKRW+0.37%
2.19 TKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Biopharma Stock analysis

What does GC Biopharma do? GC Biopharma Corp generates revenue through the production and sale of pharmaceutical products such as blood products, general products, vaccines, over-the-counter drugs, diagnostic reagents, placental injections, cell therapies, and blood diagnostic products. The company also offers genome analysis services. Its primary customers include healthcare providers and institutions requiring pharmaceuticals and diagnostic solutions. The firm targets segments focused on biopharmaceutical manufacturing and genomic healthcare services. Green Cross Corp, the parent company, operates under the same business model, emphasizing pharmaceutical manufacturing and genomic services. The company's product portfolio spans blood-related treatments, vaccines, and advanced diagnostic tools, catering to both general medical needs and specialized healthcare applications. Revenue streams are derived from direct sales of these products and services to healthcare sectors. The business model integrates the production of traditional pharmaceuticals with innovative genomic services, creating a diversified revenue base. Key segments include blood product manufacturing, vaccine development, and diagnostic reagent sales, alongside cell therapy and placental injection offerings. Customers are primarily healthcare institutions and providers seeking comprehensive pharmaceutical and diagnostic solutions. GC Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Biopharma stock

Enterprise Value (EV) of GC Biopharma is 2.24 T KRW in 2025.

Enterprise Value (EV) of GC Biopharma changed from 2.33 T KRW to 2.24 T KRW, representing a -3.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) GC Biopharma since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s KRW, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' KRW varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s GC Biopharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — GC Biopharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — GC Biopharma